Use of Diagnostic Measures in Chronic Obstructive Pulmonary Disease (COPD) in Routine Practice and Their Impact on Treatment Decisions

Use of Diagnostic Measures (Including Blood Eosinophil Counts) and Their Impact on Lung Specialists' Treatment Decisions in Patients With COPD in Germany

This study will evaluate the diagnostic measures (including blood eosinophil counts) commonly used by lung specialist's in routine clinical care of subjects with COPD in Germany and how these diagnostic tests influence the physician's treatment decisions. The study will be conducted in three parts. In the first part, lung specialist's, who will not participate in the survey, will develop doctor's questionnaire. The second part is an interventional cross-sectional study, wherein approximately 30 lung specialists will be enrolled and data on their perspective on diagnosis and treatment of COPD subjects will be collected via the revised doctor's questionnaire. The third part is a retrospective non-interventional study where each doctor will collect retrospective data from selected subjects with COPD from the time of informed consent up to 12 months before. The retrospective data will be collected from subject files of approximately 250 subjects with COPD.

Study Overview

• Status: Completed
• Conditions: Pulmonary Disease, Chronic Obstructive
• Intervention / Treatment: Other: Doctor's questionnaire; Other: Subject file

• Study Type: Observational
• Enrollment (Actual): 251

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany, 10625
    • GSK Investigational Site
  • Berlin, Germany, 13057
    • GSK Investigational Site
  • Baden-Wuerttemberg
    • Bruchsal, Baden-Wuerttemberg, Germany, 76646
      • GSK Investigational Site
    • Ulm, Baden-Wuerttemberg, Germany, 89073
      • GSK Investigational Site
  • Bayern
    • Garmisch-Partenirchen, Bayern, Germany, 82467
      • GSK Investigational Site
    • Nuernberg, Bayern, Germany, 90489
      • GSK Investigational Site
  • Brandenburg
    • Beelitz, Brandenburg, Germany, 14547
      • GSK Investigational Site
    • Cottbus, Brandenburg, Germany, 03050
      • GSK Investigational Site
    • Fuerstenwalde, Brandenburg, Germany, 15517
      • GSK Investigational Site
    • Kyritz, Brandenburg, Germany, 16866
      • GSK Investigational Site
    • Potsdam, Brandenburg, Germany, 14467
      • GSK Investigational Site
  • Hessen
    • Frankfurt, Hessen, Germany, 60389
      • GSK Investigational Site
    • Wiesbaden, Hessen, Germany, 65183
      • GSK Investigational Site
  • Mecklenburg-Vorpommern
    • Rostock, Mecklenburg-Vorpommern, Germany, 18107
      • GSK Investigational Site
  • Nordrhein-Westfalen
    • Guetersloh, Nordrhein-Westfalen, Germany, 33330
      • GSK Investigational Site
    • Menden, Nordrhein-Westfalen, Germany, 58706
      • GSK Investigational Site
    • Warendorf, Nordrhein-Westfalen, Germany, 48231
      • GSK Investigational Site
  • Rheinland-Pfalz
    • Koblenz, Rheinland-Pfalz, Germany, 56068
      • GSK Investigational Site
  • Sachsen
    • Leipzig, Sachsen, Germany, 04357
      • GSK Investigational Site
    • Leipzig, Sachsen, Germany, 04103
      • GSK Investigational Site
    • Leipzig, Sachsen, Germany, 04157
      • GSK Investigational Site
  • Sachsen-Anhalt
    • Halberstadt, Sachsen-Anhalt, Germany, 38820
      • GSK Investigational Site
    • Halle, Sachsen-Anhalt, Germany, 06108
      • GSK Investigational Site
    • Hettstedt, Sachsen-Anhalt, Germany, 06333
      • GSK Investigational Site
    • Lutherstadt Wittenberg, Sachsen-Anhalt, Germany, 06886
      • GSK Investigational Site
  • Schleswig-Holstein
    • Schleswig, Schleswig-Holstein, Germany, 24837
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Approximately 30 lung specialists (up to 50) in Germany with sufficient number of COPD subjects under supervision in a hospital or office based setting will be enrolled in the study. Data from the survey of lung specialists and retrospective medical data of 250 subjects with COPD under supervision of the 30 lung specialists (up to 50) enrolled in the study will be included in the analysis.

Description

Inclusion Criteria:

For participating centers (Sample 1: 30 lung specialists from Germany)

• More than 10 years of experience in respiratory medicine
• At least 500 subjects under supervision in hospital- or office-based setting: a) Focus on obstructive lung diseases. b) Board certification. c) Informed consent to participate in this study and to share files of consenting subjects.

For subjects (Sample 2: 250 COPD subjects from these 30 doctors from sample 1)

• Written informed consent to use his/her data.
• Age >=40 years
• Pack years >10, current or former smoking
• Duration of COPD: >=1 year since COPD diagnosis record in subject files (also confirmed by spirometry)
• No concurrent asthma diagnosis
• At least one year of documented disease history at participating study doctors and have to be under the care of the before mentioned physician during this time because of COPD.

Exclusion Criteria:

• Subjects who are pregnant and breastfeeding (in the last 12 months)
• Subjects currently participating in any interventional study
• Subjects with severe comorbidities which would have influence on the COPD therapy

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Lung specialist; Approximately 30 lung specialists in Germany with a sufficient number of COPD subjects under supervision will be enrolled in the study to document physician's attitudes on COPD diagnosis and therapy, and to document data on about 250 subjects with COPD.	Other: Doctor's questionnaire; The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.
Subjects with COPD; Data from approximately 250 subjects with COPD under supervision of lung specialists enrolled in the study will be analyzed.	Other: Subject file; All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of physicians with usage of diagnostic tests in routine clinical practice	The data on diagnostic test including blood eosinophil count commonly used by lung specialists in routine clinical practice will be obtained from doctor's questionnaire.	Up to 12 months
Number of physician reported rationale for choice of diagnostic test	The reasons for choice of diagnostic test will be determined from doctor's questionnaires and from medical chart review.	Up to 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of physician reported reasons for blood eosinophil test selection	The reasons blood eosinophil test selection will be analyzed using data from doctor's questionnaires.	Up to 12 months
Number of physician reported reasons for drug selection	The selection of drugs by lung specialists for subjects with COPD will be analyzed using information obtained from medical chart review.	Up to 12 months
Number of subjects with use of other diagnostic measures	Number of subjects with use of other diagnostic measures such as spirometry, X-ray, thoracic computer tomography and specific blood tests will be analyzed using data from subject files.	Up to 12 months
Number of subjects with use of patient reported outcome (PRO) assessment	Number of subjects with use of questionnaires like COPD assessment test (CAT) and dyspnea assessment will be analyzed using data from subject files.	Up to 12 months
Number of subjects with a history of respiratory medication	Number of subjects with a history of respiratory medication will be analyzed using data from subject files.	Up to 12 months
Number of subjects receiving current medication	Number of subjects receiving current medication will be analyzed using data from subject files.	Up to 12 months
Number of subjects receiving COPD maintenance treatment	Number of subjects receiving COPD maintenance treatment will be analyzed using data from subject files.	Up to 12 months
Number of subjects receiving immunosuppressive treatment	Number of subjects receiving immunosuppressive treatment will be analyzed using data from subject files.	Up to 12 months
Number of subjects receiving allergic treatment	Number of subjects receiving allergic treatment will be analyzed using data from subject files.	Up to 12 months
Number of subjects receiving oral corticosteroids (OCS) for exacerbations	Number of subjects with maintenance and rescue use of OCS for exacerbations will be analyzed using data from subject files.	Up to 12 months
Number of subjects with use of antibiotics	Number of subjects with use of antibiotics will be analyzed using data from subject files.	Up to 12 months
Number of subjects receiving any COPD medication	Number of subjects receiving any COPD medication will be analyzed using data from subject files.	Up to 12 months
Number of subjects with history of exacerbations	Number of subjects with history of exacerbations will be analyzed using data from subject files.	Up to 12 months
Number of subjects with hospitalization for COPD	Number of subjects with hospitalization for COPD will be analyzed using data from subject files.	Up to 12 months
Number of subjects with emergency room visits related to COPD	Number of subjects with emergency room visits related to COPD will be analyzed using data from subject files.	Up to 12 months
Number of subjects with concomitant diseases	Number of subjects with concomitant diseases will be analyzed using data from subject files.	Up to 12 months

Collaborators and Investigators

• Sponsor: GlaxoSmithKline
• Collaborators: Institut Dr. Schauerte (IDS)

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 19, 2018
• Primary Completion (ACTUAL): August 30, 2018
• Study Completion (ACTUAL): August 30, 2018

Study Registration Dates

• First Submitted: March 8, 2018
• First Submitted That Met QC Criteria: March 8, 2018
• First Posted (ACTUAL): March 14, 2018

Study Record Updates

• Last Update Posted (ACTUAL): January 15, 2019
• Last Update Submitted That Met QC Criteria: January 11, 2019
• Last Verified: January 1, 2019

More Information

Terms related to this study

• Keywords: COPD; diagnostic test; blood eosinophil count; doctor's questionnaire; Lung specialist
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: 207733

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No